Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Accelerate Pluripotent Stem Cell Differentiation into Neuroectoderm

Technology #20170241

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Human Embryonic Stem CellsEpidermis, neurons, pigment cellsDifference between stem cell and progenitor cell
Categories
Researchers
Ann Parr, MD, PhD
Assistant Professor, Department of Neurosurgery
External Link (www.neurosurgery.umn.edu)
James Dutton, PhD
Associate Professor, Department of Genetics, Cell Biology and Development
External Link (www.stemcell.umn.edu)
Patrick Walsh
Researcher, Department of Neurosurgery
Managed By
Kevin Anderson
Technology Licensing Officer 612-624-8293
Patent Protection

PCT Patent Application Filed
Publications
Defined Culture Conditions Accelerate Small-molecule-assisted Neural Induction for the Production of Neural Progenitors from Human-induced Pluripotent Stem Cells
Cell Transplantation, Volume: 26 issue: 12, page(s): 1890-1902

Generates 90% neuro progenitor cells in under 24 hours

This new method obtains populations of neural progenitor cells derived from human pluripotent stem cells (hPSCs). For obtaining primitive neuroectoderm in particular, it uses specific growth factor and signaling inhibitors to cause undifferentiated hPSCs to transition to a neural phenotype within just 24 hours.

Increases efficiency of neuronal differentiation protocols

Current methods to generate ectoderm in vitro requires at least 6 days, which is then followed by additional developmental time for creating neuronal cell type. By reducing the neuroectoderm generating time frame to less than 24 hours, this technology creates a new, accelerated time frame for the developmentally later events to occur. This time frame increases efficiency for any existing neuronal differentiation protocol. This method is currently the simplest and most efficient platform upon which protocols for deriving cell types of all neural lineages can be built, and is a vast improvement upon existing methods. Experiments can now be planned, executed and data analyzed with limited loss in productivity due to down-time or pursuit of failed experimental branches.

Phase of Development

  • Pre-clinical validation

Benefits

  • Greatly accelerates time to differentiation
  • Increases efficiency of neural differentiation protocols
  • Experiments can be planned, executed and analyzed with limited down-time

Features

  • Neural progenitor cells derived from human pluripotent stem cells (hPSCs)
  • For primitive neuroectoderm, specific growth factor and signaling inhibitors cause undifferentiated hPSCs to transition to a neural phenotype within just 24 hours
  • Reduces differentiation time from 6 days to 24 hours
  • Simplest and most efficient platform for deriving cell types of all neural lineages

Applications

  • Neural differentiation of pluripotent stem cells
  • Labs producing neural tissue
  • Cell research companies


Interested in Licensing?
The University relies on industry partners to further develop and ultimately commercialize this technology. The license is for the sale, manufacture or use of products claimed by the patents. Please contact Kevin Anderson to share your business needs and licensing and technical interests in this technology.